New Jersey, USA-based Imunon announced new translational data from the Phase II OVATION 2 Study of IMNN-001, an ...

We look forward to advancing this program to a Phase 3 pivotal trial, which remains on track to start this quarter." In this analysis increases in IL-12 levels were sampled in the peritoneal fluid ...

Imunon (IMNN) announced new translational data from ongoing analyses of results from the Company’s Phase 2 OVATION 2 Study of IMNN-001, its ...

Results from OVATION 2 Study continue to validate TheraPlas® technology, demonstrating DNA-mediated production of key anti-cancer immune cytokines following treatment IMNN-001 continues to show ...